Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 15:59:59 2024-05-24 EDT 		5-day change 1st Jan Change
9.99 USD +1.32% Intraday chart for Astellas Pharma Inc. +5.38% -16.05%
05-21 Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Business Summary

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.

Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Number of employees: 14,484

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1,296,163 100.0 % 1,518,619 100.0 % +17.16%

Sales per region

JPY in Million2022Weight2023Weight Delta
United States
43.0 %
537,452 41.5 % 652,441 43.0 % +21.40%
Established Markets
23.6 %
315,162 24.3 % 358,407 23.6 % +13.72%
Japan
17.3 %
258,758 20.0 % 262,303 17.3 % +1.37%
International
9.5 %
110,081 8.5 % 144,735 9.5 % +31.48%
Greater China
5.3 %
66,305 5.1 % 80,011 5.3 % +20.67%
Other
1.4 %
8,406 0.6 % 20,722 1.4 % +146.51%

Managers

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Kitamura Atsushi DFI
 Director of Finance/CFO 52 10-31
Kenji Yasukawa CHM
 Chairman 63 86-03-31
Katsuyoshi Sugita CMP
 Compliance Officer - 22-09-30
Yoshitsugu Shitaka CTO
 Chief Tech/Sci/R&D Officer - -
Tadaaki Taniguchi CTO
 Chief Tech/Sci/R&D Officer - -
Tomokazu Fujisawa BRD
 Director/Board Member 65 06-08-31
Noriyuki Uematsu BRD
 Director/Board Member 63 16-05-31
Hiroko Sakai BRD
 Director/Board Member 63 83-03-31
Atsushi Kamide IRO
 Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Takashi Tanaka BRD
 Director/Board Member 67 21-05-31
Mamoru Sekiyama BRD
 Director/Board Member 74 17-05-31
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Tatsuro Ishizuka BRD
 Director/Board Member 68 19-05-31
Noriyuki Uematsu BRD
 Director/Board Member 63 16-05-31
Eriko Sakurai BRD
 Director/Board Member 63 -
Tomokazu Fujisawa BRD
 Director/Board Member 65 06-08-31
Haruko Shibumura BRD
 Director/Board Member 59 19-05-31
Hiroko Sakai BRD
 Director/Board Member 63 83-03-31
Hiroo Sasaki BRD
 Director/Board Member 68 18-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,809,663,075 1,788,505,828 ( 98.83 %) 16,561,677 ( 0.9152 %) 98.83 %

Shareholders

NameEquities%Valuation
BlackRock Fund Advisors
3.662 %
66,273,504 3.662 % 638 M $
Nippon Life Insurance Co.
2.851 %
51,588,000 2.851 % 496 M $
BlackRock Japan Co. Ltd.
2.478 %
44,846,700 2.478 % 431 M $
Mitsubishi UFJ Asset Management Co., Ltd.
1.581 %
28,611,000 1.581 % 275 M $
Astellas Pharma Director Incentive Plan
0.8877 %
16,065,000 0.8877 % 155 M $
BlackRock (Netherlands) BV
0.4359 %
7,887,833 0.4359 % 76 M $
BlackRock Investment Management (UK) Ltd.
0.4294 %
7,771,247 0.4294 % 75 M $
FIL Investments (Japan) Ltd.
0.4226 %
7,648,446 0.4226 % 74 M $
AMF Tjänstepension AB (Investment Management)
0.3712 %
6,718,000 0.3712 % 65 M $
State Street Global Advisors Ltd.
0.3566 %
6,453,869 0.3566 % 62 M $
NameEquities%Valuation
RhumbLine Advisers LP
0.002096 %
37,924 0.002096 % 354 703 $
GAMMA Investing LLC
0.000133 %
2,400 0.000133 % 22 447 $
PNC Investments LLC
0.000017 %
307 0.000017 % 2 871 $
Operose Advisors LLC
0.000005 %
90 0.000005 % 842 $
First Horizon Advisors, Inc.
0.000002 %
37 0.000002 % 346 $

Holdings

NameEquities%Valuation
POSEIDA THERAPEUTICS, INC.
8.64%
 8,333,333 8.64% 17,083,333 $
TAYSHA GENE THERAPIES, INC.
3.89%
 7,266,342 3.89% 16,712,587 $
ASTELLAS PHARMA INC.
0.04%
 731,000 0.04% 7,032,907 $
FIBROGEN, INC.
5.03%
 4,968,367 5.03% 5,067,734 $
ONCOLYS BIOPHARMA INC.
3.57%
 727,200 3.57% 3,211,664 $

Company contact information

Astellas Pharma, Inc.

2-5-1 Nihonbashi-Honcho Chuo-Ku

103-8411, Tokyo

+81 3 3244 3000

http://www.astellas.com
address Astellas Pharma Inc.(ALPMY)

Group companies

NameCategory and Sector
Astellas BV
Logo Astellas BV

Astellas BV

Financial ConglomeratesFinance

Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands.

Financial Conglomerates

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,566 JPY
Average target price
1,991 JPY
Spread / Average Target
+27.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock
  5. Company Astellas Pharma Inc.